A high proportion of drugs currently coming to market exert their action in the body by inhibition of a target enzyme involved in a particular body function or in a bacterium, protozoon, or virus causing an infection. This book extends the previous volume in providing a comprehensive coverage of more recently recognised target enzymes and their known inhibitors, and within this framework of knowledge demonstrates how the drug designer uses all available information to develop a specific therapeutic agent. Drug design is an interdisciplinary art and the text illustrates the pathway followed from the initial design concept and synthesis of an inhibitor through its in vitro and in vivo assessments to clinical trial, a process involving chemists, biochemists, pharmacologies, and clinicians.